🇺🇸 FDA
Patent

US 10260069

Selective antisense compounds and uses thereof

granted A61PA61P25/00

Quick answer

US patent 10260069 (Selective antisense compounds and uses thereof) held by Ionis Pharmaceuticals, Inc. expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P25/00